Senescence marker protein 30(SMP30) serves as a potential prognostic indicator in hepatocellular carcinoma
详细信息 查看官网全文
- 英文论文题名：Senescence marker protein 30(SMP30) serves as a potential prognostic indicator in hepatocellular carcinoma
- 论文作者：Zhou Sufang
- 英文论文作者：Zhou Sufang ; Guangxi Medical University
- 年：2016
- 作者机构：Guangxi Medical University;
- 英文论文关键词：Prognostic indicator ; Hepatocellular Carcinoma ; Methylation
- 会议召开时间：2016-11-04
- 会议录名称：第十一届全国免疫学学术大会摘要汇编
- 英文会议录名称：Abstracts of 2016 CSI Congress on Immunology
- 语种：英文
- 分类号：R735.7
- 学会代码：IGMD
- 会议名称：第十一届全国免疫学学术大会
- 会议地点：中国安徽合肥
- 主办单位：中国免疫学会
- 学会名称：中国免疫学会
- 页数：1
- 文件大小：232k
- 原文格式：D
- 会议级别：全国
摘要
Background: Senescence marker protein 30(SMP30) has been identified as a tumor-related molecule of hepatocellular carcinoma(HCC), although the mechanism is not fully understood. Objective: We aimed to explore the clinical significance and underlying mechanisms of SMP30 expression in HCC.Methods: The mRNA and protein expression levels of SMP30 were assessed in tissues and cell lines using RT-qPCR, western blot, Oncomine analyses and tissue microarray-immunohistochemistry. The frequency of genetic alterations in SMP30 was determined from TCGA liver hepatocellular carcinoma dataset using the c Bio Portal. The DNA methylation status of 4 CpG sites of SMP30 was evaluated by pyrosequencing. Biological pathway enrichment and biological process annotation were performed on the genes co-expressed with SMP30 using the PANTHER. Results: In the current study, the preferentially expression of SMP30 in normal liver was observed, and the SMP30 in HCC tissues significantly reduced when compared with that in paired adjacent non-tumor tissues. The reduced expression of SMP30 was very noticeably related to larger tumor size, enhanced TNM and worse survival in HCC patients. The down-regulation of SMP30 in HCC might be mediated by DNA methylation. Moreover, genes co-expressed with SMP30 may affect the prognosis through apoptotic process, biological adhesion and blood coagulation by PANTHER analyses. Conclusions: Our studies have indicated that the SMP30 may serve as a candidate of HCC clinical prognostic marker and a potential therapeutic target.
Background: Senescence marker protein 30(SMP30) has been identified as a tumor-related molecule of hepatocellular carcinoma(HCC), although the mechanism is not fully understood. Objective: We aimed to explore the clinical significance and underlying mechanisms of SMP30 expression in HCC.Methods: The mRNA and protein expression levels of SMP30 were assessed in tissues and cell lines using RT-q PCR, western blot, Oncomine analyses and tissue microarray-immunohistochemistry. The frequency of genetic alterations in SMP30 was determined from TCGA liver hepatocellular carcinoma dataset using the c Bio Portal. The DNA methylation status of 4 Cp G sites of SMP30 was evaluated by pyrosequencing. Biological pathway enrichment and biological process annotation were performed on the genes co-expressed with SMP30 using the PANTHER. Results: In the current study, the preferentially expression of SMP30 in normal liver was observed, and the SMP30 in HCC tissues significantly reduced when compared with that in paired adjacent non-tumor tissues. The reduced expression of SMP30 was very noticeably related to larger tumor size, enhanced TNM and worse survival in HCC patients. The down-regulation of SMP30 in HCC might be mediated by DNA methylation. Moreover, genes co-expressed with SMP30 may affect the prognosis through apoptotic process, biological adhesion and blood coagulation by PANTHER analyses. Conclusions: Our studies have indicated that the SMP30 may serve as a candidate of HCC clinical prognostic marker and a potential therapeutic target.
Background: Senescence marker protein 30(SMP30) has been identified as a tumor-related molecule of hepatocellular carcinoma(HCC), although the mechanism is not fully understood. Objective: We aimed to explore the clinical significance and underlying mechanisms of SMP30 expression in HCC.Methods: The mRNA and protein expression levels of SMP30 were assessed in tissues and cell lines using RT-q PCR, western blot, Oncomine analyses and tissue microarray-immunohistochemistry. The frequency of genetic alterations in SMP30 was determined from TCGA liver hepatocellular carcinoma dataset using the c Bio Portal. The DNA methylation status of 4 Cp G sites of SMP30 was evaluated by pyrosequencing. Biological pathway enrichment and biological process annotation were performed on the genes co-expressed with SMP30 using the PANTHER. Results: In the current study, the preferentially expression of SMP30 in normal liver was observed, and the SMP30 in HCC tissues significantly reduced when compared with that in paired adjacent non-tumor tissues. The reduced expression of SMP30 was very noticeably related to larger tumor size, enhanced TNM and worse survival in HCC patients. The down-regulation of SMP30 in HCC might be mediated by DNA methylation. Moreover, genes co-expressed with SMP30 may affect the prognosis through apoptotic process, biological adhesion and blood coagulation by PANTHER analyses. Conclusions: Our studies have indicated that the SMP30 may serve as a candidate of HCC clinical prognostic marker and a potential therapeutic target.
引文